Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “overweight” rating reissued by research analysts at Piper Jaffray Companies in a research report issued on Wednesday, The Fly reports. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price points to a potential upside of 47.33% from the company’s previous close.

TTPH has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 28th. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $11.00 target price on the stock. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $11.63.

Shares of Tetraphase Pharmaceuticals (TTPH) opened at $5.43 on Wednesday. The stock has a market cap of $281.71, a price-to-earnings ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a twelve month low of $4.91 and a twelve month high of $9.93.

In related news, Director L Patrick Gage bought 3,880 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average price of $6.45 per share, with a total value of $25,026.00. Following the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total transaction of $54,425.00. Following the sale, the insider now directly owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $108,000. Voya Investment Management LLC lifted its position in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the period. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at about $147,000. Finally, Ameriprise Financial Inc. purchased a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at about $162,000. 58.28% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Tetraphase Pharmaceuticals (TTPH) Earns Overweight Rating from Piper Jaffray Companies” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/tetraphase-pharmaceuticals-ttph-earns-overweight-rating-from-piper-jaffray-companies.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.